PACB

Over the past six months, several events have impacted PACB's stock price. In Q1 2026, PacBio reported flat revenue year-over-year, which missed analyst forecasts, but a non-GAAP loss per share beat estimates. Consumables revenue saw growth, while instrument sales declined due to promotional activities, competitive dynamics, academic funding constraints, and macroeconomic challenges. The company announced collaborations with Lucid Genomics and Covaris. Analysts decreased the price target for PACB. Basecamp Research selected PacBio HiFi Sequencing for its Trillion Gene Atlas Initiative. PacBio announced the sale of its short-read sequencing assets to bolster liquidity and focus on its core HiFi technology. The upcoming commercial launch of the SPRQ-Nx chemistry platform is anticipated to improve the economics of HiFi sequencing and drive demand. The stock has experienced significant volatility.